<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f750327c-00a6-48d0-9a87-b5b0af53a3c3"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">ERYTHROMYCIN TABLETS, USP<br/>
      </content>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20240801"/>
   <setId root="75a0bd5a-d09f-483b-bfd8-f8343b149eb2"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001627975" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="13b87ef6-cf33-4763-ada3-1dd99c66b124"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0093-5571" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Erythromycin</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Erythromycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERYTHROMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERYTHROMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="40UAA97IT9" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (35 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5Y0974F5PW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (110000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G4U024CQK6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PNR0YF693Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 102</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-5571-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-5571-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA214549" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210504"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" displayName="pink" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TV;2E</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>modified oval</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0093-5572" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Erythromycin</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Erythromycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERYTHROMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERYTHROMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="40UAA97IT9" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (35 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5Y0974F5PW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (110000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G4U024CQK6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7T9FYH5QMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 101</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PNR0YF693Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 102</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-5572-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-5572-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA214549" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210504"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" displayName="pink" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TV;3E</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>modified oval</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_07ffc28f-e7a6-45e3-919c-50dc6622e741">
               <id root="57a1d95e-f8e9-48dd-ae55-bbf2586caf9c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets and other antibacterial drugs, erythromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1169e6a0-ead9-4001-8a5e-d150626eb08c">
               <id root="4612d0d2-db0e-427f-b9c2-e3dbf9bc726a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Erythromycin tablets, USP are an antibacterial product containing erythromycin USP, in a unique, nonenteric film coating for oral administration. Erythromycin tablets, USP are available in two strengths containing either 250 mg or 500 mg of erythromycin, USP base.</paragraph>
                  <paragraph>Erythromycin, USP is produced by a strain of <content styleCode="italics">Saccharopolyspora erythraea</content> (formerly <content styleCode="italics">Streptomyces erythraeus</content>) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Erythromycin, USP is a white or slightly yellow crystal, slightly soluble in water, and soluble in alcohol, chloroform, and ether. Erythromycin, USP is known chemically as (3<content styleCode="italics">R</content>*, 4<content styleCode="italics">S</content>*, 5<content styleCode="italics">S</content>*, 6<content styleCode="italics">R</content>*, 7<content styleCode="italics">R</content>*, 9<content styleCode="italics">R</content>*, 11<content styleCode="italics">R</content>*, 12<content styleCode="italics">R</content>*, 13<content styleCode="italics">S</content>*, 14<content styleCode="italics">R</content>*)-4-[(2,6-Dideoxy-3-<content styleCode="italics">C</content>-methyl-3-<content styleCode="italics">O</content>-methyl-α-L-<content styleCode="italics">ribo</content>-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-<content styleCode="italics">xylo</content>-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. The molecular formula is C<sub>37</sub>H<sub>67</sub>NO<sub>13</sub>, and the molecular weight is 733.94. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>FDA approved dissolution test specifications differ from USP</paragraph>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="LINK_effac86a-3061-4c7a-8ddb-393209ebdb6f">
                     <id root="1c1cb522-4914-46d7-a245-4804aff77858"/>
                     <code code="51727-6" codeSystem="2.16.840.1.113883.6.1" displayName="INACTIVE INGREDIENT SECTION"/>
                     <title>Inactive Ingredients</title>
                     <text>
                        <paragraph>Colloidal silicon dioxide, croscarmellose sodium, crospovidone type B, FD&amp;C Red No. 40, hydroxypropyl cellulose, hypromellose 2910, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, povidone K30, propylene glycol, sorbic acid, talc, titanium dioxide, and tri-sodium citrate dihydrate. </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bf98f750-1cbd-4bdd-97dd-788944a8769a">
               <id root="b2d3b680-a7aa-4d1d-ba0a-7a2ca8416905"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely bound to plasma proteins. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental barrier, but fetal plasma levels are low. The drug is excreted in human milk. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</paragraph>
                  <paragraph>In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5% of the administered dose can be recovered in the active form in the urine.</paragraph>
                  <paragraph>Optimal blood levels are obtained when erythromycin is given in the fasting state (at least 1/2 hour and preferably 2 hours before meals). Bioavailability data are available from Arbor Pharmaceuticals.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="LINK_eb57c69c-84f4-47e5-a36f-3ec38021d99b">
                     <id root="905511ed-cd5a-4abd-b7e1-5dfc3d9cfd83"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Mechanism of Action</content>
                           </content>
                        </paragraph>
                        <paragraph>Erythromycin acts by inhibition of protein synthesis by binding 50S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Resistance</content>
                           </content>
                        </paragraph>
                        <paragraph>The major route of resistance is modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity while efflux can also be significant.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Interactions with Other Antimicrobials</content>
                           </content>
                        </paragraph>
                        <paragraph>Antagonism exists <content styleCode="italics">in vitro</content> between erythromycin and clindamycin, lincomycin, and chloramphenicol.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Antimicrobial Activity</content>
                           </content>
                        </paragraph>
                        <paragraph>Erythromycin has been shown to be active against most isolates of the following bacteria both <content styleCode="italics">in vitro</content> and in clinical infections as described in the <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_65dcef4f-b333-498d-8de0-ca36a36f8147">INDICATIONS AND USAGE</linkHtml>
                           </content> section.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gram-positive Bacteria:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Corynebacterium diphtheriae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Corynebacterium minutissimum</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Listeria monocytogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus </content>(resistant organisms may emerge during treatment)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pyogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gram-negative Bacteria:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bordetella pertussis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Legionella pneumophila</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Neisseria gonorrhoeae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Other Microorganisms:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Chlamydia trachomatis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Entamoeba histolytica</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mycoplasma pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treponema pallidum</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ureaplasma urealyticum</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available, <content styleCode="bold">
                              <content styleCode="underline">but their clinical significance is unknown.</content>
                           </content>
                        </paragraph>
                        <paragraph>At least 90% of the following bacteria exhibit <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for erythromycin. However, the efficacy of erythromycin in treating clinical infections due to these bacteria has not been established in adequate and well controlled clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gram-positive Bacteria:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Viridans group streptococci</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gram-negative Bacteria:</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Moraxella catarrhalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Susceptibility Testing</content>
                           </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_65dcef4f-b333-498d-8de0-ca36a36f8147">
               <id root="f68fec8c-122d-4cc4-84e5-439dcc3bdae6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets and other antibacterial drugs, erythromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                  <paragraph>Erythromycin tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below:</paragraph>
                  <paragraph>Upper respiratory tract infections of mild to moderate degree caused by <content styleCode="italics">Streptococcus pyogenes</content>; <content styleCode="italics">Streptococcus pneumoniae</content>; <content styleCode="italics">Haemophilus influenzae</content> (when used concomitantly with adequate doses of sulfonamides, since many strains of <content styleCode="italics">H. influenzae</content> are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information).</paragraph>
                  <paragraph>Lower respiratory tract infections of mild to moderate severity caused by <content styleCode="italics">Streptococcus pyogenes</content> or <content styleCode="italics">Streptococcus pneumoniae</content>.</paragraph>
                  <paragraph>Listeriosis caused by <content styleCode="italics">Listeria monocytogenes</content>.</paragraph>
                  <paragraph>Respiratory tract infections due to <content styleCode="italics">Mycoplasma pneumoniae</content>.</paragraph>
                  <paragraph>Skin and skin structure infections of mild to moderate severity caused by <content styleCode="italics">Streptococcus pyogenes</content> or <content styleCode="italics">Staphylococcus aureus</content> (resistant staphylococci may emerge during treatment).</paragraph>
                  <paragraph>Pertussis (whooping cough) caused by <content styleCode="italics">Bordetella pertussis</content>. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.</paragraph>
                  <paragraph>Diphtheria: Infections due to <content styleCode="italics">Corynebacterium diphtheriae</content>, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.</paragraph>
                  <paragraph>Erythrasma: In the treatment of infections due to <content styleCode="italics">Corynebacterium minutissimum</content>.</paragraph>
                  <paragraph>Intestinal amebiasis caused by <content styleCode="italics">Entamoeba histolytica</content> (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents.</paragraph>
                  <paragraph>Acute pelvic inflammatory disease caused by <content styleCode="italics">Neisseria gonorrhoeae</content>: Erythrocin<sup>TM</sup> Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by <content styleCode="italics">N. gonorrhoeae</content> in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.</paragraph>
                  <paragraph>Erythromycins are indicated for treatment of the following infections caused by <content styleCode="italics">Chlamydia trachomatis</content>: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to <content styleCode="italics">Chlamydia trachomatis</content>.<sup>3</sup>
                  </paragraph>
                  <paragraph>When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma urealyticum</content>.<sup>3</sup>
                  </paragraph>
                  <paragraph>Primary syphilis caused by <content styleCode="italics">Treponema pallidum</content>. Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy.</paragraph>
                  <paragraph>Legionnaires’ Disease caused by <content styleCode="italics">Legionella pneumophila</content>. Although no controlled clinical efficacy studies have been conducted, <content styleCode="italics">in vitro</content> and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="LINK_2a30050e-cc4c-4eaf-a522-0c0ac8aa8618">
                     <id root="d771f119-5517-42a6-883f-df1d57a24dd8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Prophylaxis</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Prevention of Initial Attacks of Rheumatic Fever</content>
                           </content>
                        </paragraph>
                        <paragraph>Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis).<sup>1</sup> Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Prevention of Recurrent Attacks of Rheumatic Fever</content>
                           </content>
                        </paragraph>
                        <paragraph>Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).<sup>1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5c59c66a-d011-407d-86ba-953de29cd57e">
               <id root="fee7cd30-8d90-4f6f-85ab-1a3ee933c8d9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic.</paragraph>
                  <paragraph>Erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_93953a05-4ae1-48c2-8316-c9c940cda067">PRECAUTIONS - Drug Interactions</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Do not use erythromycin concomitantly with HMG CoA reductase inhibitors (statins) that are extensively metabolized by CYP 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4fbd2047-6626-4240-bf0d-279e8758d483">
               <id root="a622eca0-329e-4eaf-93e5-ded9e2c2b836"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="LINK_a0098c75-037e-4782-b8f8-af1048e60f47">
                     <id root="28e1ea93-5580-449f-bbcc-7bdbe017d7ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hepatotoxicity</title>
                     <text>
                        <paragraph>There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c2856d77-c8ba-4540-8656-89bb335c6a79">
                     <id root="7a99cdb2-9426-466e-a3e9-269efa55059a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>QT Prolongation</title>
                     <text>
                        <paragraph>Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_db25864d-8c1e-45cf-99cd-57d9d012ec33">
                     <id root="6bac33c0-4ed6-4aa5-a7bf-cc3ef9bb14a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Syphilis in Pregnancy</title>
                     <text>
                        <paragraph>There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent congenital syphilis. Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_237b50db-35fb-4d28-ab23-20db32c3b36a">
                     <id root="02d2e0e0-769a-4a22-a50d-891c72f8ad1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="italics">Clostridium difficile </content>Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridium difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including erythromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph> If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ac040e9c-8769-425c-a1f4-279693e8cee3">
                     <id root="0187d349-38fc-4f61-96cf-fcd4ca587cec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_93953a05-4ae1-48c2-8316-c9c940cda067">PRECAUTIONS - Drug Interactions</linkHtml>
                           </content>).</paragraph>
                        <paragraph>There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine. This interaction is potentially life-threatening, and may occur while using both drugs at their recommended doses (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_93953a05-4ae1-48c2-8316-c9c940cda067">PRECAUTIONS - Drug Interactions</linkHtml>
                           </content>).</paragraph>
                        <paragraph> Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels (see package insert for lovastatin).<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_de13c4c1-bb01-4f77-8d17-381ee5f75959">
               <id root="199d5fb6-c0e4-4233-85df-cced05838916"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20240801"/>
               <component>
                  <section ID="LINK_02179eeb-31ff-455d-ae5a-449a3f451688">
                     <id root="e6f3f1f5-beea-41ca-a50d-2159f2e0c6f4"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Prescribing erythromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <paragraph>Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_bf98f750-1cbd-4bdd-97dd-788944a8769a">CLINICAL PHARMACOLOGY</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving erythromycin therapy.</paragraph>
                        <paragraph>There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for pertussis prophylaxis, seven neonates (5%) developed symptoms of non-bilious vomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A possible dose-response effect was described with an absolute risk of IHPS of 5.1% for infants who took erythromycin for 8 to 14 days and 10% for infants who took erythromycin for 15 to 21 days.<sup>2</sup> Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as pertussis or neonatal Chlamydia trachomatis infections), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs.</paragraph>
                        <paragraph>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted.</paragraph>
                        <paragraph>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</paragraph>
                        <paragraph> Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early pregnancy.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b1c9675c-9c99-4d07-ba3e-ceff2634a466">
                     <id root="c56629f6-3a1e-43b7-97dd-020ddcffe66e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be counseled that antibacterial drugs including erythromycin tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When erythromycin tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by erythromycin tablets or other antibacterial drugs in the future.</paragraph>
                        <paragraph>Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_93953a05-4ae1-48c2-8316-c9c940cda067">
                     <id root="1433e32c-5c7c-4bb4-aedf-49bb5d64af56"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Theophylline</content>
                           </content>
                        </paragraph>
                        <paragraph>Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</paragraph>
                        <paragraph>There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin serum concentrations of approximately 35%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to coadministration of theophylline could result in subtherapeutic concentrations of erythromycin.</paragraph>
                        <paragraph>Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.</paragraph>
                        <paragraph>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.</paragraph>
                        <paragraph>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with oral anticoagulants may be more pronounced in the elderly.</paragraph>
                        <paragraph>Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system (CYP3A). Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving erythromycin.<br/>
                        </paragraph>
                        <paragraph>The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ergotamine/dihydroergotamine</content>
                        </paragraph>
                        <paragraph>Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_5c59c66a-d011-407d-86ba-953de29cd57e">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines</content>
                        </paragraph>
                        <paragraph>Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</paragraph>
                        <paragraph>
                           <content styleCode="italics">HMG-CoA Reductase Inhibitors</content>
                        </paragraph>
                        <paragraph>Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Sildenafil (Viagra</content>
                           <content styleCode="italics">
                              <sup>®</sup>
                           </content>
                           <content styleCode="italics">)</content>
                        </paragraph>
                        <paragraph>Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should be considered (see Viagra<sup>®</sup> package insert).</paragraph>
                        <paragraph>There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, <br/> methyl-prednisolone, cilostazol, vinblastine, and bromocriptine.</paragraph>
                        <paragraph>Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_5c59c66a-d011-407d-86ba-953de29cd57e">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</paragraph>
                        <paragraph>Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT<sub>c</sub> interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias, have been observed (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_5c59c66a-d011-407d-86ba-953de29cd57e">CONTRAINDICATIONS</linkHtml>
                           </content>). In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.</paragraph>
                        <paragraph>There have been post-marketing reports of drug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes, most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_5c59c66a-d011-407d-86ba-953de29cd57e">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Colchicine</content>
                           </content>
                        </paragraph>
                        <paragraph> Colchicine is a substrate for both CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin. If coadministration of colchicine and erythromycin is necessary, the starting dose of colchicine may need to be reduced, and the maximum colchicine dose should be lowered. Patients should be monitored for clinical symptoms of colchicine toxicity (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3d5596e8-2b25-4b6e-b5a1-6956f6d61604">
                     <id root="ae72c5ba-7546-4eca-948a-58fba5135892"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test
Interactions</title>
                     <text>
                        <paragraph>Erythromycin interferes with the fluorometric determination of urinary catecholamines.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5dc90e1d-f101-4f78-9436-e006f6514dd8">
                     <id root="90f1a258-e964-45b1-8898-d5c93c760f19"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis,
Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term oral dietary studies conducted with erythromycin stearate in rats up to 400 mg/kg/day and in mice up to about 500 mg/kg/day (approximately 1 to 2 fold of the maximum human dose on a body surface area basis) did not provide evidence of tumorigenicity. Erythromycin stearate did not show genotoxic potential in the Ames, and mouse lymphoma assays or induce chromosomal aberrations in CHO cells. There was no apparent effect on male or female fertility in rats treated with erythromycin base by oral gavage at 700 mg/kg/day (approximately 3 times the maximum human dose on a body surface area basis).</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4b85c988-933f-4f13-a615-51bae6c8650d">
                     <id root="bb7e7397-8701-431b-a43c-5852535bc094"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Teratogenic Effects</content>
                           </content>
                        </paragraph>
                        <paragraph>There is no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on a body surface area) prior to and during mating, during gestation, and through weaning. No evidence of teratogenicity or embryotoxicity was observed when erythromycin base was given by oral gavage to pregnant rats and mice at 700 mg/kg/day and to pregnant rabbits at 125 mg/kg/day (approximately 1 to 3 times the maximum recommended human dose).</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a107a512-f41b-4e85-8edd-12a96781ae8a">
                     <id root="c23567b3-8752-43c7-b448-b7ae3ecc0916"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>The effect of erythromycin on labor and delivery is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a67daea8-1557-42ad-96f6-33863b1e69bf">
                     <id root="6f2f502c-a558-4881-8105-68f29cb5755d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_18473a63-bc77-4821-b50e-b2f3dbdad0ad">
                     <id root="f9fa4543-5b7b-40d8-a41c-7b2b77945fee"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>See <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_65dcef4f-b333-498d-8de0-ca36a36f8147">INDICATIONS AND USAGE</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_c1906e2f-e48c-43dd-8ec5-1b5825aba074">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_26a3bd6e-e465-4fc7-84f2-731f5ede2167">
                     <id root="1f346ba3-c005-40f8-ab0c-689e5929aae6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced hearing loss (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_ca4359af-8fea-4231-99f6-4d05da0fe4ac">ADVERSE REACTIONS</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_c1906e2f-e48c-43dd-8ec5-1b5825aba074">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin (see <content styleCode="bold">
                              <linkHtml href="#www.splportal.comLINK_93953a05-4ae1-48c2-8316-c9c940cda067">PRECAUTIONS - Drug Interactions</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Erythromycin tablets (250 mg) contain 6.5 mg (0.3 mEq) of sodium per tablet.</paragraph>
                        <paragraph>Erythromycin tablets (500 mg) contain 13 mg (0.6 mEq) of sodium per tablet.</paragraph>
                        <paragraph>The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20240801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ca4359af-8fea-4231-99f6-4d05da0fe4ac">
               <id root="88df0e3c-56b0-41c8-b0a8-98844f27023e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic dysfunction and/or abnormal liver function test results may occur (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes (see <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_4fbd2047-6626-4240-bf0d-279e8758d483">WARNINGS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely.</paragraph>
                  <paragraph>There have been reports of interstitial nephritis coincident with erythromycin use.</paragraph>
                  <paragraph>There have been rare reports of pancreatitis and convulsions.</paragraph>
                  <paragraph>There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">To report suspected adverse reactions, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_f2feb814-9113-4cc4-8f21-70e668d58620">
               <id root="c7480ed6-df63-4e14-bed6-1607f4f068de"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures should be instituted.</paragraph>
                  <paragraph>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c1906e2f-e48c-43dd-8ec5-1b5825aba074">
               <id root="f4bbd39e-708f-4c42-b6b2-6eba7d51aec5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>In most patients, erythromycin tablets are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when erythromycin tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adults</content>
                  </paragraph>
                  <paragraph>The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Children</content>
                  </paragraph>
                  <paragraph>Age, weight, and severity of the infection are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe infections this dosage may be doubled but should not exceed 4 g per day.</paragraph>
                  <paragraph>In the treatment of streptococcal infections of the upper respiratory tract (e.g., tonsillitis or pharyngitis), the therapeutic dosage of erythromycin should be administered for at least ten days.</paragraph>
                  <paragraph>The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal upper respiratory tract infections for the prevention of recurring attacks of rheumatic fever in patients allergic to penicillin and sulfonamides.<sup>1</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Conjunctivitis of the Newborn Caused by Chlamydia trachomatis</content>
                  </paragraph>
                  <paragraph>Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks.<sup>3</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pneumonia of Infancy Caused by Chlamydia trachomatis</content>
                  </paragraph>
                  <paragraph>Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Urogenital Infections During Pregnancy Due to Chlamydia trachomatis</content>
                  </paragraph>
                  <paragraph>Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours or 250 mg by mouth four times a day should be used for at least 14 days.<sup>3</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For adults with uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis, when tetracycline is contraindicated or not tolerated</content>
                  </paragraph>
                  <paragraph>500 mg of erythromycin by mouth four times a day for at least 7 days.<sup>3</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For patients with nongonococcal urethritis caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated</content>
                  </paragraph>
                  <paragraph>500 mg of erythromycin by mouth four times a day for at least seven days.<sup>3</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Primary syphilis</content>
                  </paragraph>
                  <paragraph>30 to 40 g given in divided doses over a period of 10 to 15 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Acute Pelvic Inflammatory Disease Caused by N. gonorrhoeae</content>
                  </paragraph>
                  <paragraph>500 mg Erythrocin<sup>TM</sup> Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours for 7 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Intestinal Amebiasis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Adults</content>
                     </content>
                  </paragraph>
                  <paragraph>500 mg every 12 hours or 250 mg every 6 hours for 10 to 14 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Children</content>
                     </content>
                  </paragraph>
                  <paragraph>30 to 50 mg/kg/day in divided doses for 10 to 14 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pertussis</content>
                  </paragraph>
                  <paragraph>Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Legionnaires’ Disease</content>
                  </paragraph>
                  <paragraph>Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b7a86b93-5812-4274-b109-3eb177f8e556">
               <id root="aecd6a47-0426-418f-88ae-c72de47dc2b7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Erythromycin tablets, USP are supplied as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold">250 mg:</content> Each pink, film-coated, modified oval shaped tablet, debossed with TV on one side and 2E on the other side contains 250 mg of erythromycin, USP. Tablets are available in bottles of 30 (NDC 0093-5571-56) and 100 (NDC 0093-5571-01).</paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg:</content> Each pink, film-coated, modified oval shaped tablet, debossed with TV on one side and 3E on the other side contains 500 mg of erythromycin, USP. Tablets are available in bottles of 30 (NDC 0093-5572-56) and 100 (NDC 0093-5572-01).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended storage</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25ºC (68°F to 77ºF); excursions permitted between 15ºC to 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_beee642a-a235-4beb-85e7-b47ab03d1ff6">
               <id root="ae687fd0-98e5-4f6f-b0a4-ca16f07e2816"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association: Prevention of Rheumatic Fever. Circulation. 78(4): 1082-1086, October 1988.</item>
                     <item>Honein, M.A., et al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. The Lancet 1999:354 (9196): 2101-5.</item>
                     <item>Data on file, Arbor Pharmaceuticals, LLC.</item>
                  </list>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_45b704ce-f3a1-47da-834a-36f3814e564a">
               <id root="61392c8f-dd41-4fa8-a61c-a8e39551f4a9"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>Manufactured in Bulgaria By:<br/>
                     <content styleCode="bold">Balkanpharma-Dupnitsa AD<br/>
                     </content>Dupnitsa 2600, Bulgaria</paragraph>
                  <paragraph>Manufactured For:<br/>
                     <content styleCode="bold">Teva Pharmaceuticals <br/>
                     </content>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. A 8/2024</paragraph>
               </text>
               <effectiveTime value="20240801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1cb2f86b-9b46-4559-85c8-795ab4ecdf82">
               <id root="cff74994-ea6b-4c65-b5d5-dfa1184b859c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0093-5571-56</paragraph>
                  <paragraph>Erythromycin Tablets, USP<br/>
250 mg</paragraph>
                  <paragraph>Rx only<br/>
30 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>erythromycin</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3d8c468e-9c50-46a5-92c8-a362998bef3e">
               <id root="f0e6b34c-ecb7-4a2d-8a5d-02962b0b540d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0093-5572-56</paragraph>
                  <paragraph>Erythromycin Tablets, USP<br/>
500 mg</paragraph>
                  <paragraph>Rx only<br/>
30 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20240801"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>eryth</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>